FDA Awards Priority Review Voucher to Ipsen Biopharmaceuticals for Rare Pediatric Disease Product

Summary

The US Food and Drug Administration (FDA) has issued a priority review voucher to Ipsen Biopharmaceuticals, Inc. for its rare pediatric disease product palovarotene, manufactured by Ipsen Biopharmaceuticals, Inc., under the Federal Food, Drug, and Cosmetic Act (FD&C Act).